Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.

Pharmacological reviews - 1 Sept 2025

Du Yafei, Karatekin Feride, Wang Wendy Kehan, Hong Wanjin, Boopathy Gandhi T K

Abstract excerpt

Epidermal growth factor receptor (EGFR) plays a crucial role in tumorigenesis across multiple cancer types. EGFR mutations, overexpression, amplifications, dysregulated signaling, and impaired receptor downregulation drive cancer progression, particularly in non-small cell lung cancer, glioblastoma, colorectal cancer, gastric cancer, and head and neck cancers. Over the past decades, EGFR-targeted therapies,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Source

Identifiers

PMID: 40675056
DOI: 10.1016/j.pharmr.2025.100076

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.PMID 40675056Read ↗

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired ResistanceSemantic proximity Read ↗

Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor.Semantic proximity Read ↗

Genetic alterations shaping tumor response to anti-EGFR therapies.Semantic proximity Read ↗

Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistanceSemantic proximity Read ↗

Overcoming Resistance in EGFR-Mutant Cancers: A Comprehensive Review of Inhibitor Evolution and SAR-Based Design.Semantic proximity Read ↗

Emerging strategies to overcome resistance to third-generation EGFR inhibitors.Semantic proximity Read ↗

Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?Semantic proximity Read ↗

Epidermal growth factor receptor mutations in breast Cancer: Therapeutic challenges and way forward.Semantic proximity Read ↗

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.Semantic proximity Read ↗

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.Semantic proximity Read ↗

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung CancerSemantic proximity Read ↗

Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.